Christopher Whitehead Email

COO . MEKanistic Therapeutics

Current Roles

Employees:
11
Revenue:
$852.5k
About
Led by cancer research pioneers, MEKanistic is advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window by inhibiting compensatory resistance pathways at the same time, avoiding inherent toxicity challenges of multi-compound treatments.
MEKanistic Therapeutics Address
1015 Glenwood Avenue
Minneapolis, MN
United States
MEKanistic Therapeutics Email